



# La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique

François Vercruyse

## ► To cite this version:

François Vercruyse. La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique. Médecine humaine et pathologie. 2018. dumas-02068314

HAL Id: dumas-02068314

<https://dumas.ccsd.cnrs.fr/dumas-02068314>

Submitted on 14 Mar 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique

François Vercruyse

## ► To cite this version:

François Vercruyse. La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique. Médecine humaine et pathologie. 2018. <hal-02068314>

HAL Id: dumas-02068314

<https://dumas.ccsd.cnrs.fr/dumas-02068314>

Submitted on 14 Mar 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





U.F.R. DES SCIENCES MEDICALES

Thèse pour l'obtention du

**DIPLOME D'ÉTAT DE DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement le 14 septembre 2018

Par Monsieur François Vercruyse

Né le 20 mars 1990 à Pau

**La stratégie de traitement par biothérapie de la  
maladie de Still de l'adulte dépend de la dichotomie  
phénotypique**

Président du Jury

Monsieur le Professeur Thierry Schaeverbeke

Membres du Jury

Monsieur le Professeur Christophe Richez  
Madame la Professeur Estibaliz Lazaro  
Monsieur le Docteur Jean-Philippe Vernhes

Directrice de thèse

Madame le Docteur Marie-Élise Truchetet

Rapporteur de thèse

Monsieur le Docteur Jean-Philippe Vernhes





U.F.R. DES SCIENCES MEDICALES

Thèse pour l'obtention du

**DIPLOME D'ÉTAT DE DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement le 14 septembre 2018

Par Monsieur François Vercruyse

Né le 20 mars 1990 à Pau

**La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique**

Président du Jury

Monsieur le Professeur Thierry Schaeverbeke

Membres du Jury

Monsieur le Professeur Christophe Richez  
Madame la Professeur Estibaliz Lazaro  
Monsieur le Docteur Jean-Philippe Vernhes

Directrice de thèse

Madame le Docteur Marie-Élise Truchetet

Rapporteur de thèse

Monsieur le Docteur Jean-Philippe Vernhes



**Prénom: François**  
**Nom: Vercruyse**  
**Spécialité : Rhumatologie**  
**U.F.R. des Sciences Médicales, Université de Bordeaux**

---

## **La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique**

**Introduction:** Le phénotype de la maladie de Still de l'adulte (MSA) peut être dichotomisé en une forme systémique et une forme articulaire chronique. A l'ère où les biothérapies et notamment le blocage des interleukines (IL)-1 et 6 jouent un rôle prépondérant dans son traitement, leurs place dans la stratégie thérapeutique reste à préciser. Cette étude avait pour objectif d'identifier des facteurs prédictifs cliniques ou biologiques de réponse préférentielle à l'anakinra ou au tocilizumab, et d'identifier si le choix de biothérapie et son délai d'initiation influençaient les chances de sevrage cortisonique.

**Méthodes:** Une étude exploratoire multicentrique rétrospective a inclus tous les patients atteints de MSA et ayant reçu une biothérapie dans trois hôpitaux régionaux jusqu'à 2018. Leur caractéristiques cliniques et biologiques au diagnostic et les données relatives aux traitements ont été recueillies. Une analyse univariée a été effectuée en utilisant le test statistique non-paramétrique de Mann-Whitney pour les variables quantitatives et le test exact de Fisher pour les variables qualitatives.

**Résultats:** Vingt-sept patients ont été inclus. Tous les patients sauf un ont atteint la rémission soit sous anakinra soit sous tocilizumab. La réponse au traitement dépendait du phénotype clinique : la présence d'arthrite et un phénotype articulaire chronique étaient associés à une réponse thérapeutique préférentielle pour le tocilizumab ( $p=0.017$  et  $p=0.0009$  respectivement), alors qu'une forme systémique et l'absence d'arthrite étaient associées à une réponse thérapeutique préférentielle à l'anakinra ( $p=0.017$  et  $p=0.0009$  respectivement). Le tocilizumab était associé à de meilleures chances de sevrage cortisonique ( $p=0.029$ ) quel que soit son délai d'initiation ou sa place en terme de ligne thérapeutique.

**Conclusion:** Cette étude souligne l'importance de la dichotomisation phénotypique de la MSA et ses implications thérapeutiques. Ces résultats devraient nous permettre de mieux catégoriser les patients atteints de MSA et nous aider à codifier leur traitement.

**Mots-clés:** *Maladie de Still de l'Adulte, Traitements Biologiques, Corticoïdes, Maladies auto-inflammatoires*

**Prénom: François**  
**Nom: Vercruyse**  
**Spécialité : Rhumatologie**  
**U.F.R. des Sciences Médicales, Université de Bordeaux**

---

## **Adult-Onset Still's Disease Biological Treatment Strategy Depends on the Phenotypic Dichotomy**

**Objectives:** Adult-onset Still's disease (AOSD) phenotype can be dichotomized in systemic or chronic articular forms. As biologicals and particularly interleukin (IL)-1 and IL-6 blockers play a more and more prominent role in the treatment, their place requires clarification. This study aimed to identify factors predictive of treatment response to anakinra or tocilizumab, and investigate whether the choice of biotherapy and delays in the initiation of biotherapy influenced the likelihood of steroid discontinuation.

**Methods:** A multicenter exploratory retrospective study included all patients diagnosed with AOSD and receiving biological treatments in three regional hospitals until 2018. Clinical and biological characteristics at diagnosis and treatment related data were collected. The non-parametric Mann-Whitney test was used to perform univariate analysis for quantitative variables, and Fisher's exact test was used for qualitative variables.

**Results:** Twenty-seven patients were included. All but one patient achieved remission with either anakinra or tocilizumab. Treatment responses depended on disease phenotype: the presence of arthritis and a chronic articular phenotype were associated with a preferential response to tocilizumab with  $p=0.0009$  and  $p=0.017$  respectively, whereas the systemic form and the absence of arthritis were associated with a preferential response to anakinra with  $p=0.0009$  and  $p=0.017$  respectively. Tocilizumab increased the likelihood of corticosteroid withdrawal ( $p=0.029$ ) regardless of delays in initiation or when it was initiated relative to other treatment in the overall therapeutic strategy.

**Conclusion:** This study highlights the therapeutic implications of the phenotypic dichotomy of AOSD and should help us better codify AOSD treatment.

**Keywords:** *Adult-Onset Still's disease, Biologicals, Corticosteroids, Miscellaneous Rheumatic and Inflammatory Diseases*

# Remerciements

À notre président du Jury, *Monsieur le Professeur Thierry Schaeeverbeke*,

Pour m'avoir transmis votre passion pour la Rhumatologie dès le début de mon externat et tout au long de mon internat,

Pour me faire l'honneur d'accompagner une fois de plus mon travail,

Je vous prie d'accepter ma très sincère gratitude et mon plus grand respect.

À nos membres du Jury,

*Monsieur le Docteur Jean-Philippe Vernhes*, également rapporteur de ce travail, pour avoir accepté d'être le premier à juger ce travail, pour votre soutien votre pédagogie et surtout votre confiance dès le début de mon Internat qui m'ont permis de m'épanouir dans ma vie professionnelle, pour m'avoir enseigné les nuances de gris,

*Monsieur le Professeur Christophe Richez*, pour votre disponibilité et votre gentillesse,

*Madame la Professeur Estibaliz Lazaro*, pour avoir incarné un exemple inspirant de rigueur de précision et d'équilibre dans votre exercice de la médecine,

À *vous tous*, pour avoir accordé votre intérêt à ce travail en acceptant de le juger, je vous prie de croire en l'expression de ma sincère considération.

À notre directrice de thèse, *Madame la Docteur Marie-Élise Truchetet*,

Pour avoir accepté de participer à la direction de ce travail,

Pour la confiance que vous m'avez apportée,

Pour avoir su trouver l'équilibre entre me conseiller et m'autonomiser tout au long de la réalisation de ce travail.

À ma famille,

*Papa*, pour avoir toujours su trouver les mots justes pour me faire grandir et avancer, pour m'avoir inculqué ton intuitivité et ton ouverture d'esprit.

*Maman*, pour m'avoir appris à ne pas me reposer sur mes acquis, pour m'avoir toujours aidé à fixer mes priorités, pour ta patience, pour tous les sacrifices que tu as fait pour moi.

*Sœur*, pour tes précieux conseils et ton écoute dans la confidence, pour ton honnêteté et ton courage, pour ton soutien dans les moments de L...

*Ben*, pour être un véritable grand-frère, pour m'avoir encouragé vers ma passion pour la montagne, pour m'avoir initié aux joies de la varappe, pour savoir me faire oublier mes soucis en un clin d'œil.

*Grand-Père*, pour avoir toujours été un modèle et un exemple pour moi, pour ton infinie et précieuse sagesse, pour m'avoir enseigné la joie de l'apiculture, pour ton humilité et ta philanthropie.

*Grand-Mère*, pour m'avoir appris l'importance de ma famille, pour ton émotivité.

À *Lucille*,

Parce que te rencontrer est la meilleure chose qui me soit arrivée,

Pour me faire partager et découvrir ce monde où, à tes côtés, tout paraît possible,

Parce qu'il n'est pas d'aventure que je ne souhaite partager avec toi.

À mes amis,

À *Tristan*, pour ton soutien infaillible, ton oreille attentive, ta confiance, ta mélomanie et ton humour souvent salvateur, pour avoir réussi à rendre inoubliable une année aussi difficile que la P1,

À *Vincent* (et à *Georges*), pour avoir rendu mémorables ces heures passées à bosser ensemble, pour ce paquet de pâtes vide, et surtout pour ces traversées de névés en juillet et pour ces moments en montagne, pour ton amour de la Suze et pour ces deux semestres en colocation : « Guy ! »,

À *Marc*, pour ces heures à ski/snow ou à grimper, pour ces conférences en binôme, pour Rudy's à NY, pour ta gestion de la friteuse, pour ton amour de la Suze et pour ces deux semestres en colocation : « Guy ! », ah et au fait Marc : oui ça caille ici, et oui il est pour toi ce café.

À *Guy* et à *Guy* : « Guy ! »,

À *Petit*, *Thibault*, *Fabien*, *Olive*, *Binôme*, pour avoir réussi à rendre géniales ces trois années d'externat !

À tous ceux qui m'ont soutenu et entouré pendant ces années.

À mes consœurs et confrères,

À *Nicolas*, *Nadia*, *François*, *Emilie*, *Alexandre*, *Xavier*, *Laurence*, *Thomas*, Qui dès mes premiers pas en tant qu'interne ont su, en plus de m'apprendre énormément sur le plan scientifique, me faire réfléchir aux questions éthiques indispensables auxquelles tout médecin doit être préparé,

Qui ont fait preuve de générosité et de patience pour me transmettre leur savoir et leur précieuse expérience.

Enfin, aux équipes paramédicales,

À *Patricia*, pour ta bienveillance, pour toutes ces attentions, pour tout, merci.

À toutes les *infirmières, aides-soignantes, ASH du service de Rhumatologie de Pellegrin*,

À *Françoise et Annick* pour ces repas pendant mes gardes, ces fins de journée après les consultations,

Mais aussi à toutes celles et ceux des services de rhumatologie médecine interne et dermatologie de Dax, Pau ou Libourne,

Pour avoir souvent su égayer certaines journées,

Pour ces gestes ou attentions arrivant toujours à point nommé.

# Table des matières

<b>Remerciements.....</b>	<b>8</b>
<b>Table des matières.....</b>	<b>12</b>
<b>Liste des abréviations.....</b>	<b>13</b>
<b>Introduction.....</b>	<b>15</b>
<b>Article scientifique .....</b>	<b>18</b>
Introduction.....	20
Methods.....	22
<i>Study design and data collection.....</i>	22
<i>Outcome measurements.....</i>	23
<i>Statistical analysis .....</i>	24
Results.....	26
<i>Patients' characteristics.....</i>	26
<i>Biological treatment efficacy .....</i>	27
<i>Predictive factors for preferential responses to anakinra or tocilizumab .....</i>	29
<i>Likelihood of steroid withdrawal depending on the specific biotherapy and delays in initiation of biotherapy.....</i>	30
Discussion.....	32
Conclusion.....	38
Declarations.....	39
References.....	41
<b>Tables .....</b>	<b>44</b>
Table 1.....	44
Table 2.....	45
Table 3.....	46
Table 4.....	47
<b>Serment d'Hippocrate .....</b>	<b>48</b>

# Liste des abréviations

## Français

- MSA : Maladie de Still de l'Adulte
- CIVD : coagulation intra-vasculaire disséminée
- SAM : syndrome d'activation macrophagique

## Anglais

- AOSD: Adult-Onset Still's Disease
- IL: interleukin
- INF: interferon
- TNF: tumor necrosis factor
- rHLH: reactive hemophagocytic lymphohistiocytosis
- bDMARD: biological disease-modifying antirheumatic drugs
- SoJIA: systemic-onset juvenile idiopathic arthritis
- CRP: C-reactive protein
- LDH: lactate dehydrogenase
- NSAIDs: nonsteroidal anti-inflammatories
- csDMARD: conventional synthetic disease-modifying anti-rheumatic drugs
- ENT : ear-nose-throat
- CK: creatine kinase
- Anti-ENA: anti-extractable nuclear antigen
- ANCA: antineutrophil cytoplasmic antibody
- ACPA: positive anticitrullinated protein antibody
- ANA : antinuclear antibodies
- Anti-DNA: antideoxyribonucleic acid
- RF: rheumatoid factor
- IQR: interquartile range
- RCT: randomized controlled trial
- JAK: janus kinase

*« La médecine est un art qu'on exerce, en attendant qu'on le découvre. »*  
- Emile Deschamps

*« L'art de la médecine consiste à distraire le malade pendant que la nature le guérit. »*  
- Voltaire

# Introduction

Ce travail de thèse s'inscrit dans le contexte de l'élaboration d'une cohorte nationale sur la maladie de Still nommée RaDiCo-ACOSTILL ayant pour but de fédérer autour des patients un consortium de cliniciens pour mieux décrire la maladie, de constituer une biobanque afin d'effectuer des études physiopathologiques et de constituer une file active de patients suffisamment importante pour de futurs essais thérapeutiques.

La Maladie de Still de l'Adulte (MSA) est une maladie inflammatoire systémique rare décrite par Eric George Bywaters en 1971 affectant principalement le jeune adulte et se manifestant par des symptômes similaires à ceux de l'Arthrite Juvénile Idiopathique à début systémique (SoJIA) décrite chez l'enfant par Sir George Frederic Still en 1897. Elle affecte autant les hommes que les femmes, son incidence annuelle est estimée entre 0.16 et 0.62 pour 100 000 personnes, et sa prévalence aux environs de 1 à 24 par millions.

Les symptômes cardinaux sont classiquement une fièvre hectique volontiers vespérale ; des arthralgies et/ou arthrites ; une éruption cutanée typiquement saumonée, évanescante, vespérale et concomitante du pic fébrile ; et une odynophagie. On observe également régulièrement une polyadénopathie et une splénomégalie. Les anomalies biologiques sont dominées par un syndrome inflammatoire majeur, une hyperferritinémie avec un effondrement de sa fraction glycosylée, et d'éventuelles anomalies hématologiques.

La physiopathologie de la MSA est encore imparfaitement comprise. Il s'agit d'une maladie auto-inflammatoire d'origine multifactorielle : une génétique prédisposante non mendélienne ; des facteurs environnementaux (principalement infectieux) ; et un déséquilibre immunologique impliquant une hyperactivation ou dérégulation du macrophage, du polynucléaire neutrophile et de l'inflammasome.

Récemment, il a été mis en évidence une dichotomie entre deux phénotypes majeurs de MSA : une forme dite « systémique » au cours de laquelle la fièvre, l'éruption cutanée, l'atteinte hématologique, parfois des atteintes viscérales et un syndrome inflammatoire biologique marqué sont au premier plan ; et une forme rhumatologique dite « articulaire chronique » au cours de laquelle un tableau de polyarthrite prédomine accompagné de marqueurs biologiques d'inflammation souvent moins élevés.

Cette représentation dichotomique de la MSA est non seulement alimentée par des observations cliniques mais aussi par des profils cytokiniques différents. Ce déséquilibre cytokinique se ferait plutôt en faveur de l'IL-1 $\beta$  IL-18 and IFN- $\gamma$  dans la forme systémique, alors que l'IL-6 IL-8 le TNF-alpha et l'IL-17 prévaudraient dans la forme articulaire chronique.

Le cours de la maladie est imprédictible et peut prendre de multiples évolutions : mono-poussée, forme polycyclique, formes chroniques systémiques ou articulaires. Le pronostic de la MSA est donc triple: fonctionnel pour les formes érosives polyarticulaires chroniques ; vital plus particulièrement lors des formes systémiques par la survenue de sérite ou d'un syndrome d'activation macrophagique pouvant aboutir à une coagulation intravasculaire disséminée (CIVD); et enfin iatrogène étant donné l'exposition fréquente de ces patients à de fortes doses prolongées de corticoïdes avec les effets indésirables qu'on leur connaît, et du fait des complications notamment infectieuses des traitements biologiques prescrits.

Ce polymorphisme clinique et pronostique représente un défi majeur et complique la prise en charge et la stratégie thérapeutique initiale d'une MSA au diagnostic. Elle explique également en partie l'absence de recommandations consensuelles sur la stratégie thérapeutique notamment concernant les traitements biologiques au cours de la MSA. La prise en charge d'une MSA est donc actuellement encore largement empirique ou basée sur de trop rares case-reports ou études rétrospectives.

Cependant les traitements biologiques, hors AMM, occupent une place de plus en plus importantes dans la stratégie thérapeutique. Une méta-analyse récente montre que les traitements biologiques bloquant l'IL-1 et l'IL-6 sont les plus efficaces dans la MSA, et ont de surcroît un effet d'épargne cortisonée.

Point d'importance majeure, la dichotomie ne serait pas seulement clinique et cytokinique mais peut-être également thérapeutique en ce qui concerne les traitements biologiques comme le suggèrent certains auteurs. La forme systémique de la MSA répondrait préférentiellement au blocage du récepteur de l'IL-1 (actuellement principalement représenté par l'anakinra) alors que la forme articulaire répondrait mieux au blocage du récepteur de l'IL-6 (actuellement principalement représenté par le tocilizumab).

Entériner la place prépondérante des ces deux biothérapies dans le traitement de la MSA a donc un intérêt majeur afin d'éviter la survenue de complications vitales fonctionnelles ou iatrogènes.

Enfin, arriver à prédire dès le diagnostic le traitement biologique auquel le patient est le plus susceptible de répondre est séduisant car cela permettrait potentiellement de gagner du temps dans la prise en charge avec les conséquences pronostiques que cela implique, et d'éviter de potentielles déboires thérapeutiques à nos patients.

L'objectif principal de cette étude était donc d'identifier au diagnostic des facteurs prédictifs cliniques et biologiques de bonne réponse préférentielle à l'anakinra ou au tocilizumab. Les objectifs secondaires étaient d'étudier si le choix de biothérapie (anakinra ou tocilizumab) et son délai d'initiation influençaient les chances de sevrage cortisonique dans la MSA, et de décrire les caractéristiques cliniques et biologiques des patients atteints de MSA en Aquitaine.

## Article scientifique

Est présenté ici le manuscrit de l'article soumis pour publication à la revue *Arthritis Research and Therapy*.

# **Adult-Onset Still's Disease Biological Treatment Strategy Depends on the Phenotypic Dichotomy**

François Vercruyse<sup>a</sup>, Thomas Barnetche<sup>a</sup>, Estibaliz Lazaro<sup>b</sup>, Emilie Shipley<sup>c</sup>, François Lifermann<sup>d</sup>, Alexandre Balageas<sup>e</sup>, Xavier Delbrel<sup>f</sup>, Bruno Fautrel<sup>g</sup>, Christophe Richez<sup>a</sup>, Thierry Schaeverbeke<sup>a</sup>, Marie-Elise Truchetet<sup>a</sup>

<sup>a</sup> Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Service de Rhumatologie, Place Amélie Raba Léon, 33076 Bordeaux, France

<sup>b</sup> Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Service de Médecine Interne, Avenue Magellan, 33600 Pessac, France

<sup>c</sup> Centre Hospitalier de Dax, Service de Rhumatologie, Boulevard Yves du Manoir, 40100 Dax, France

<sup>d</sup> Centre Hospitalier de Dax, Service de Médecine Interne, Boulevard Yves du Manoir, 40100 Dax, France

<sup>e</sup> Centre Hospitalier de Pau, Service de Rhumatologie, 4 Boulevard Hauterive, 64000 Pau, France

<sup>f</sup> Centre Hospitalier de Pau, Service de Médecine Interne, 4 Boulevard Hauterive, 64000 Pau, France

<sup>g</sup> Centre Hospitalier Universitaire de Paris, Hôpital Pitié Salpêtrière, Service de Rhumatologie, Boulevard de l'Hopital, 75013 Paris, France

## **Key messages:**

- What is already known about this subject?
  - The phenotype of adult-onset Still's disease can be dichotomized into systemic or chronic articular forms.
  - Biological treatments are dominated by IL-1 or IL-6 receptor inhibitors.
- What are the new lines of research suggested by this study?
  - The presence of arthritis and a chronic articular phenotype may be associated with a preferential response to tocilizumab, whereas the systemic form may be associated with a preferential response to anakinra.
  - Tocilizumab increases the likelihood of corticosteroid withdrawal regardless of delays in its initiation or when it is initiated relative to other treatment in the overall therapeutic strategy
- How might this impact clinical practice?
  - These results should help us better codify the treatment strategy for adult-onset Still's disease.

## Introduction

Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder. Its annual incidence is estimated to be between 0.16 and 0.62 per 100 000 persons globally(1), and its prevalence approximately 1-24 per million(2).

AOSD is an autoinflammatory disease resulting from multifactorial causes such as genetic factors and immunological imbalances involving macrophage, neutrophil and inflammasome hyperactivation or dysfunction(3).

Recent studies have concluded that there is a dichotomy between two major phenotypes of AOSD: a systemic pattern that presents with an acute onset associating high fever, skin rash, hematopoietic signs and sometimes visceral damage; and a chronic articular profile in which polyarthritis prevails(4,5). This phenotypic dichotomy is highlighted by recent studies showing that there are different cytokine imbalances in these two phenotypes. Although results may vary, this imbalance would sometimes favour interleukin (IL)-1 $\beta$ , IL-18 and interferon (IFN)-gamma production in the systemic form; whereas in the chronic articular form, IL-6, IL-8, tumor necrosis factor (TNF)-alpha and IL-17 production would predominate(6–12).

The prognosis of AOSD is unpredictable as it can manifest with polyarticular erosive disease or life-threatening manifestations such as reactive hemophagocytic lymphohistiocytosis (rHLH). The disease course is also very polymorphic, ranging from a monophasic flare to polycyclic or chronic forms. This clinical and prognostic polymorphism presents a major challenge and makes it difficult to predict the outcome at the time of diagnosis and to determine appropriate management.

Therapy is therefore usually empirical, and beside methotrexate, biologics have played an increasing role in the chronic or refractory forms. A recent meta-analysis suggested that IL-1 and IL-6 receptor inhibitors are the most effective biotherapies for AOSD(13) and have a strong steroid-sparing effect. The systemic phenotype has been suggested to respond preferentially to IL-1 receptor inhibitors, such as anakinra, while the chronic articular form shows better responses to IL-6 receptor inhibitors, such as tocilizumab(6,7,14–17).

This exploratory study therefore aimed to identify initial clinical and/or biological factors that were predictive of a preferential response to anakinra or tocilizumab. Secondary objectives were to investigate whether the choice of biotherapy (anakinra or tocilizumab) and their delay in initiation influenced the likelihood of steroid discontinuation, and to describe the clinical and biological phenotypes of patients with AOSD.

# Methods

## Study design and data collection

A multicenter exploratory retrospective study of all patients diagnosed with AOSD at Bordeaux teaching hospital and Pau and Dax peripheral hospitals until 2018 was conducted. Patients included had to be 16 years old or older, to be diagnosed with AOSD, to meet the Yamaguchi and/or Fautrel criteria, to have a chronic or refractory disease course, and to receive or have received a biological disease-modifying antirheumatic drugs (bDMARD). Exclusion criteria were: age younger than 16 years old, a diagnosis of systemic-onset juvenile idiopathic arthritis (SoJIA), an exclusion of AOSD diagnosis during disease course, Yamaguchi and Fautrel criteria not met, lack of data, absence of bDMARD during disease course.

Patients with AOSD were identified via ICD-10 code, via a diagnostic grid that automatically references autoimmune and inflammatory diseases at Bordeaux University hospital, via the bioinformatics services of each hospital, and via direct contact with the specialists treating the patients. Data regarding clinical and biological characteristics at diagnosis and treatment details were collected using a standard data extraction form. All the information was double-checked for any discrepancies.

The following demographic and clinical AOSD-related characteristics were collected: sex, date of birth, age at diagnosis, year of diagnosis, duration of disease, duration of disease at first bDMARD initiation, smoking habits, personal or familial history of rheumatic autoimmune inflammatory or neoplastic disease, type of Still's disease-related rash if present, arthralgia, arthritis, hands affected or not, early morning stiffness, myalgia, fever

characteristics, general deterioration and weight loss>4 kg, lymphadenopathy, pharyngitis, angina and visceral involvement (pleuritis, pericarditis, pulmonary hypertension).

The following biological characteristics were recorded: leukocytosis>10 000/mm<sup>3</sup>, neutrophilia>8000/mm<sup>3</sup>, eosinophilia>500/mm<sup>3</sup>, anemia with haemoglobin<12 g/dl, thrombocytosis>400 000/mm<sup>3</sup>, increased C-reactive protein (CRP) levels, maximum CRP at diagnosis, decreased albumin, increased liver enzymes, increased creatine kinase, increased lactate dehydrogenase (LDH), increased ferritin, decreased glycosylated ferritin, autoimmunity markers (antinuclear antibodies, antideoxyribonucleic acid, anti-extractable nuclear antigen, rheumatoid factor, antiβ2GP1, lupus anticoagulant, anticardiolipin), disseminated intravascular coagulation markers and rHLH markers (cytopenia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow).

Patients were classified as having two distinct disease patterns: the systemic form or the chronic articular form. In the absence of consensual criteria in this regard, this classification was based on expert opinions that was often spelled out in the medical reports, and was confronted to disease course outcome which was available due to the retrospective nature of this study.

## Outcome measurements

A modified Pouchot score (range, 0-12), which considers 12 disease-related manifestations(18) (fever, evanescent rash, pleuritis, pneumonia, pericarditis, hepatomegaly, serum ferritin levels>3000 mg/L, lymphadenopathy, white blood cell count>15 000/mm, sore throat, myalgia,

and arthritis), was applied to assess disease activity. Patients had to have a modified Pouchot score of 0 to be considered in remission.

When data were insufficient to determine this score, the effectiveness of treatment was defined as follows: effective treatment was considered when all initial symptoms and biological anomalies had resolved; partially effective treatment was considered when all but one initial symptom or biological anomaly had resolved; and ineffective treatment was considered when two or more initial symptoms or biological anomaly persisted. The attending doctors assessed disease flares and relapses.

Treatment lines were assessed as follows: nonsteroidal anti-inflammatories (NSAIDs) were not considered a treatment modality for chronic and refractory AOSD; but corticosteroids, csDMARD and especially methotrexate (both galenic forms taken together) and cyclosporine, and bDMARD (anakinra, tocilizumab, canakinumab, infliximab, and etanercept) were considered treatment lines.

### **Statistical analysis**

Quantitative variables are presented as mean with standard deviation or as median with interquartile range, and qualitative variables are presented as percentages. Analysis was performed on the following variables: all the clinical and biological manifestations included in the Yamaguchi or Fautrel criteria, common demographic characteristics, and all the symptoms or biological abnormalities usually observed during AOSD according to the literature and our personal experience. The nonparametric Mann-Whitney test was used to perform a univariate analysis of quantitative variables, and the Fisher exact test was used for qualitative variables. Calculations were

performed with STATA 13.1 SE software. P-values less than 0.05 were considered significant.

# Results

## Patients' characteristics

Twenty-seven patients were included in this study: 21 from Bordeaux teaching hospital, 4 from Dax hospital, and 2 from Pau hospital. Patient characteristics at diagnosis are described in **Table 1**.

All patients fulfilled both the Yamaguchi and Fautrel criteria. No patients had any personal or familial history of rheumatic, autoimmune, inflammatory or neoplastic disease. All patients presented with a fever above 38°C, mainly intermittent and vesperal fevers. The next most prevalent symptoms were arthralgia (96%), arthritis (52%), skin rash (81%), general deterioration (72%), and ear-nose-throat (ENT) symptoms (69%).

Eleven (40.7%) patients were classified as systemic form of disease, and 16 (59.3%) as chronic articular form.

All patients presented with elevated CRP levels. The next most commonly observed anomalies were neutrophilia (96%), low albumin (75%) and increased ferritin (73%). No patients presented with increased creatine kinase (CK), positive extractable nuclear antigen (ENA), positive antineutrophil cytoplasmic antibody (ANCA), positive anticitrullinated protein antibody (ACPA) or positive anticardiolipin. Nine patients were either ANA-positive (five), anti-DNA positive (one), or rheumatoid factor (RF)-positive (three) at diagnosis, but these results were always controlled to be negative.

The median duration of disease was 5 years (IQR 2-7) and 6.5 years (IQR 5-9) for the systemic and chronic articular forms respectively.

All patients presented a chronic refractory form of the disease, which required the off-label use of bDMARD because of failures of corticosteroids and synthetic disease-modifying antirheumatic drug (sDMARD) or necessity to reduce or stop corticosteroids.

### **Biological treatment efficacy**

**Table 2** presents the detailed responses to anakinra and tocilizumab among the patients included in the study. Twenty-six of 27 patients (96.3%) achieved remission with either anakinra or tocilizumab. The median delay in the introduction of the first biotherapy was 5 months (interquartile range (IQR), 1-21 months): this delay was median 1 month (IQR, 0-6) in the systemic form, and median 17 months (IQR, 4-38) in the chronic articular form.

A total of 15 patients received anakinra; 5 as a first-line treatment, 4 as a second-line treatment, 5 as a third-line treatment, and 1 as a fourth-line treatment. The median delay between diagnosis and the introduction of anakinra was 1.5 months (IQR, 0-14). Thirteen (86.7%) patients were responders, among which 3 (23.1%) also received methotrexate when remission was achieved. The 2 anakinra non-responders received anakinra as a third-line treatment: one had previously failed to respond to tocilizumab, the other later responded to tocilizumab and even managed to stop it.

A total of 17 patients received tocilizumab, 2 as a first-line treatment, 6 as a second-line treatment, 5 as a third-line treatment and 4 as a fourth-line treatment. The median delay between diagnosis and the introduction of tocilizumab was 17 months (IQR, 4-39 months). Fourteen patients (82.4%) were responders. Among the 3 tocilizumab nonresponders, one presented

with a systemic form and received tocilizumab as a first-line treatment but later responded to anakinra, one presented with a systemic form and received tocilizumab as a fourth-line treatment after responding to anakinra but was switched because of a suspicion of anakinra-induced toxidermia, one presented with a chronic articular form and received tocilizumab as a fourth-line treatment after failure of anakinra.

The difference of median duration of disease at the introduction of the first bDMARD in the anakinra-treated patients group and in the tocilizumab-treated patients group was statistically significant ( $p=0.04457$ ): median 2 months (IQR, 0.25-12 months) in the anakinra-treated patients, and median 14.5 (IQR, 3.25-38.25 months) in the tocilizumab-treated patients.

Eight patients (29.6%) managed to stop their biological treatment without relapse at the last known visit which ranged from 6 to more than 24 months after biological treatment discontinuation: 3 of 13 (23%) anakinra responders and 5 of 14 (35.7%) tocilizumab responders. The difference in delays in initiation of anakinra or tocilizumab was not statistically significant between those who managed to stop their biotherapy without relapse versus those who could not stop their biotherapy or those who relapsed, with a median delay of 3 months (IQR, 1.25-13.75) versus 8.5 months (IQR, 1-23.25), respectively ( $p=0.61$ ).

Five patients received both biotherapies. Two of these patients presented with a systemic form and were tocilizumab nonresponders but anakinra responders, one presented with a chronic articular form and was anakinra nonresponder but tocilizumab responder, one presented with a chronic articular form and did not respond to either biotherapy, and one

patient presented with a systemic form and responded to both biotherapies; this patient first responded to anakinra but corticosteroids couldn't be tapered so he was switched to tocilizumab in order to successfully stop corticosteroids.

One patient received canakinumab and failed to respond but was anakinra responder. Three patients received antitumor necrosis factor (TNF) agents but these treatments were not efficacious (2 etanercept, 1 infliximab): two of them presented a chronic articular form and one a systemic form.

One of 27 (3.7%) patients did not respond to either biotherapy (anakinra then tocilizumab) and died of a probably infectious-induced AOSD flare.

### Predictive factors for preferential responses to anakinra or tocilizumab

Patients who responded to either biotherapies or no biotherapy were excluded from this analysis (n=2). **Table 3** describes the univariate analysis for potential predictive factors of a good therapeutic response to anakinra or tocilizumab.

A chronic articular phenotype and the presence of arthritis were associated with a preferential response to tocilizumab (n=12/14 vs. n=3/13, p=0.0009; n=10/14 vs. n=3/13, p=0.017), whereas a systemic form and the absence of arthritis were associated with a preferential response to anakinra (n=1/14 vs. n=9/13, p=0.0009; n=3/14 vs. n=9/13, p=0.017).

No difference in biological variables was statistically predictive of treatment response, although the presence of thrombocytosis seemed to be

preferentially associated with a better response to tocilizumab than to anakinra ( $n=8/14$  vs.  $n=3/13$ ,  $p=0.123$ ).

#### **Likelihood of steroid withdrawal depending on the specific biotherapy and delays in initiation of biotherapy**

All patients received corticosteroids at diagnosis. Among the 26 patients in remission, 14 (53.8%) achieved corticosteroid withdrawal within a mean delay of 27 months: 10 (71.4%) were on tocilizumab, and 4 (28.6%) were on anakinra (**Table 2**).

**Table 4** presents the likelihood of corticosteroid withdrawal depending on treatment with anakinra and tocilizumab: tocilizumab was associated with an increased likelihood of corticosteroid withdrawal ( $p=0.029$ ), whereas anakinra did not seem to increase the likelihood of corticosteroid withdrawal ( $p=1.000$ ).

A shorter delay before the initiation of anakinra or tocilizumab was not associated with a greater likelihood of corticosteroid withdrawal among biotherapy responders. Among anakinra responders, the difference in the median delay from diagnosis to anakinra initiation between those who achieved steroid withdrawal ( $n=4$ ) and those who did not ( $n=10$ ) was not statistically significant ( $p=0.5767$ ): the median delay was 2.5 months (IQR, 0-8 months) among those who did not stop corticosteroids versus 2 months (IQR, 2-14 months) among those who stopped corticosteroids. Among tocilizumab responders, the difference in the median delay from diagnosis to tocilizumab initiation between those who achieved steroid withdrawal ( $n=11$ ) and those who did not ( $n=5$ ) was not statistically significant ( $p=0.9548$ ): the median

delay was 17 months (IQR, 9-21 months) among the tocilizumab responders who did not stop corticosteroids versus 17 months (IQR, 4-38 months) among those who stopped corticosteroids. Initiating tocilizumab as the first-line treatment rather than as a second-line or later treatment did not improve the likelihood of corticosteroid withdrawal ( $n=1/2$  vs.  $n=11/15$ ,  $p=1.000$ ). In addition, initiating tocilizumab as a first- or second-line treatment rather than as a third-line or later treatment also did not improve the likelihood of steroid withdrawal ( $n=6/8$  vs.  $n=5/9$ ,  $p=0.619$ ); similarly, initiating tocilizumab as a first-, second- or third-line treatment did not improve the likelihood of steroid withdrawal compared to that from tocilizumab used as a fourth-line treatment ( $n=9/13$  vs.  $n=2/4$ ,  $p=0.584$ ).

## Discussion

This retrospective study was conducted to evaluate bDMARDs strategies in the management of AOSD, with a special attention to predictive factors of their efficacy and their effect on corticosteroid sparing. All but one patient achieved remission with either anakinra or tocilizumab. Our results support the dichotomy of AOSD in two phenotypes: treatment responses to bDMARD depended on disease phenotype, the presence of arthritis and a chronic articular phenotype were associated with a preferential response to tocilizumab, whereas the systemic form was associated with a preferential response to anakinra. In our cohort, anakinra did not increase the likelihood of corticosteroid withdrawal but tocilizumab did, regardless of delays in initiation, or when it was initiated relative to other treatment in the overall therapeutic strategy.

The clinical and biological characteristics of the patients included in this study seem similar to those of AOSD patients reported in the literature(19), with the exception of life-threatening conditions, which have been estimated to affect as many as 15-20% of AOSD patients, while only 8% were affected in this study.

Multivariate analysis was not performed because of the sample size, a limitation inherent to rare diseases such as AOSD. Rather than aiming to look for significant differences, the goal of this study was to establish a reference for future large-scale studies and compile data from registries to confirm the results.

The distinction between systemic and chronic articular forms is not always straightforward and no consensual criteria exist to distinguish these

two phenotypes. For example a systemic form progressing for several years, who received corticosteroids for a long time and who benefited from bDMARD late in disease course, might be confused for a chronic articular form.

These results highlight the excellent efficacy of anakinra and tocilizumab in AOSD, regardless of the phenotype, but show some differences between them. However, the retrospective nature of the study is a major limitation to compare these two drugs. The choice of biotherapy may have been different depending on their availability on the year of diagnosis: anakinra was launched on the market several years before tocilizumab and the effects of anakinra and tocilizumab on AOSD were not simultaneously described.

One could argue that clinicians may have influenced the choice of biotherapy by preferentially prescribing tocilizumab to patients presenting with arthritis or a chronic articular form, analogous to rheumatoid arthritis, and therefore distorted the results. Comparing these two bDMARDs is impossible outside a randomized controlled trial (RCT) and none ever demonstrated that tocilizumab should be preferentially prescribed to AOSD patients with arthritis(5,20,21).

Yet the following results reinforce our findings. All but three of the patients included in this study were diagnosed in 2009 or later and these three received anakinra or tocilizumab after both their efficacy were described in AOSD.

A major result of our study is that anakinra responders more commonly did not have arthritis, as the absence of arthritis was statistically associated with a better response to anakinra ( $p=0.017$ ). Tocilizumab also showed less

efficiency on the systemic form. This result supports the notion that even if clinicians' choices may have been influenced by analogy to rheumatoid arthritis, their insights seem to be founded. Whether anakinra is effective for AOSD patients with joint involvement is indeed a subject of debate as the data seem to be inconsistent(4,22–25). In our study, 5 patients presenting with a chronic articular form received anakinra: 3 responded to anakinra and never received tocilizumab, one was an anakinra non-responder but responded to tocilizumab, and one responded to anakinra but had to be switched to tocilizumab in order to stop the corticosteroid.

The absence of demonstrated steroid-sparing with anakinra in this study is questionable as it demonstrated a steroid-sparing effect in several other studies(22,24,26). A channelling bias exists: the acute onset of the systemic phenotype and its potential life-threatening complications might cause the clinicians to be more cautious while tapering corticosteroids, and the tocilizumab-induced fall in CRP might reassure them. Furthermore, anakinra was made available before tocilizumab: the progressively known dramatic efficacy of anakinra may have reassured the clinicians and entice them into a faster corticosteroids tapering when tocilizumab was made available. In addition, three patients presenting a systemic form in our study were able to taper corticosteroids down to 5mg daily but the clinicians opted to maintain this dosage as a long-term therapy. Both the management and the place of corticosteroids in AOSD treatment strategy should maybe differ based on the differences between the two phenotypes.

No patients in this study responded to anti-TNF blockers, whatever the phenotype. The efficacy of these medications in AOSD is controversial, but

some studies suggest that they have a place in the treatment of the chronic articular form(27–29), while others have showed rather disappointing results(20,21,30). The excellent efficacy and clear steroid-sparing effect of tocilizumab determined in our study, concurring with the findings of a recent meta-analysis showing that AOSD patients treated with tocilizumab had a pooled remission rate of approximately 85% regardless of the phenotype(31), should make clinicians prioritize tocilizumab to anti-TNF blockers for patients with a chronic articular form of AOSD. Canakinumab is currently being investigated for this indication (NCT02204293). No patient in this study received abatacept or rituximab; the data are very limited but some authors reported efficacy in patients who fail to respond to TNF, IL-1 or IL-6 inhibition(32–37).

Physiopathological data may highlight the efficacy of IL-17 or IL-18 blockade in AOSD. A recent study investigated whether IL-18 inhibition, using the recombinant human IL-18 binding protein tadekinig alpha, is a therapeutic option in patients with AOSD in a phase 2 open-label trial(38). Half of the patients achieved remission at week 3, suggesting early therapeutic efficacy of IL-18 blockade in AOSD. IL-17(39) and INF- $\gamma$ (40) blockade have not been studied yet but should be in the near future. Janus kinase (JAK) inhibitors may also be of interest, particularly in the chronic articular form of AOSD via their blockage of IL-6 and INF- $\gamma$  pathways.

The two main goals when initiating a bDMARD in AOSD should be a complete remission and corticosteroids withdrawal or significant tapering.

This study does not reveal definitive answers regarding whether an early introduction of biologics improves the general prognosis of AOSD. We

believe that the early use of biologics in AOSD patients is worth considering. It is our impression that the earlier biologics are used, the shorter and smoother the disease course is. Similarly, other authors have suggested that biotherapies should be initiated earlier in the course of AOSD (13,19), arguing that earlier initiation may improve the prognosis mainly via a steroid-sparing effect. Notably, the results of this study suggest that the steroid-sparing effect of biologics is not influenced by delays in initiation of biological therapy.

One-quarter to one-third (29.6%) of our patients managed to stop biologics despite chronic or refractory forms of AOSD, raising the question of how and when to stop biologics in these patients. A channelling bias exists, as no predefined corticosteroids tapering strategy could be set due to the retrospective nature of this study but patients who managed to stop anakinra had all achieved remission for at least 6 to 12 months, had initially stopped corticosteroids, and then all underwent progressive reduction in their biological treatments before definitive discontinuation. Among patients who managed to stop tocilizumab, corticosteroids had always previously been stopped, and tocilizumab dosage was progressively decreased when it had been administered by perfusion or tapered when it had been administered by injections. The high percentage of patients who successfully discontinued biological treatments in our study should encourage clinicians to consider tapering biologics among patients without visceral involvement who are in clinical and biological remission for 6 to 12 months.

The first evidence-based clinical practice guidelines for the management of AOSD(41) emphasized the use of IL-6 inhibitors in the treatment of AOSD but IL-1 inhibitors were judged to be “weakly

recommended as a therapeutic agent against refractory AOSD” although one RCT and several case reports suggest otherwise. A proposal may be to treat a first flare of AOSD with corticosteroids and to introduce biologics in cases of steroid-refractory flares or as early as the second flare of AOSD. In that case, anakinra should be preferred when faced with the systemic form of AOSD, and tocilizumab in patients with the articular form. The well-known idea of a “window of opportunity” in rheumatoid arthritis may also be valid in AOSD, with the objective being to prevent the development of a self-perpetuating “cytokine storm”. Monitoring our patients’ cytokine profiles may lead to personalized tailor-made biological treatment strategies in the future, but the use of these tools in daily clinical practice remains unrealistic for now.

We need large-scale studies, prospective cohort studies, RCTs and international collaborative registries regarding this multifaceted disease. As emphasized in a recent editorial, these studies will have to be more precise about evaluating the patients’ disease course and particularly their phenotypes in order to concentrate research on the subgroup of patients with a chronic or refractory form of the disease(42). A national French cohort, the French Adult and Childhood Onset Still Disease Cohort (RaDiCo-ACOSTILL), was recently opened for inclusion and will surely help to shed light on these issues in the near future.

## Conclusion

This study supports the dichotomy of AOSD in two phenotypes and introduces the idea that treatment responses to bDMARD depend on disease phenotype. The presence of arthritis and a chronic articular phenotype seem to be associated with a preferential response to tocilizumab, whereas the systemic form seem to be associated with a preferential response to anakinra. Although further research is needed, this exploratory study highlights the therapeutic implications of the phenotypic dichotomy of AOSD. These results should help us better codify treatment strategies for AOSD.

## Declarations

### Funding

This study was not funded.

### Acknowledgments

The authors thank the patients who were involved in this study and the individuals from the rheumatology and internal medicine departments who took part in the care of these patients.

### Disclosures

François Vercruyse, Thomas Barnetche, Emilie Shipley, François Lifermann, Alexandre Balageas and Xavier Delbrel have no relevant relationship conditions or circumstances that present a potential conflict of interest regarding this study.

Estibaliz Lazaro has received consultancy fees from Roche, Novartis and UCB.

Bruno Fautrel, Marie-Elise Truchetet, Christophe Richez and Thierry Schaeverbeke have received consultancy fees and/or research funding from Abbvie, Bristol-Myers Squibb, Pfizer, Roche, Lilly, Novartis and UCB.

## **Availability of data and material and consent for publication**

The authors state that they had full access to all the data in the study and they take responsibility for the integrity of the data and the accuracy of the data analysis as well as the decision to submit them for publication.

## **Authors' contributions**

*Study conception and design:* François Vercruyse, Marie-Elise Truchetet

*Acquisition of data:* François Vercruyse

*Analysis and interpretation of data:* François Vercruyse, Thomas Barnetche, Marie-Elise Truchetet

*Drafting of manuscript:* François Vercruyse, Marie-Elise Truchetet, Thomas Barnetche

*Critical revision:* François Vercruyse, Marie-Elise Truchetet, Alexandre Balageas, Xavier Delbrel, François Lifermann, Emilie Shipley, Estibaliz Lazaro, Bruno Fautrel, Christophe Richez, Thierry Schaeverbeke

## **Ethics approval and consent to participate**

Not applicable

## **Consent for publication**

Not applicable

## References

1. Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. *Ann Rheum Dis.* 1995 Jul;54(7):587–90.
2. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still's disease: Advances in the treatment. *Best Pract Res Clin Rheumatol.* 2016 Apr;30(2):222–38.
3. Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Sèze P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. *Immunol Res.* 2015 Feb;61(1-2):53–62.
4. Maria ATJ, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions. *Autoimmun Rev.* 2014 Nov;13(11):1149–59.
5. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sèze P. Adult-onset Still's disease. *Autoimmun Rev.* 2014 Jul;13(7):708–22.
6. Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. *Rheumatology.* 2001 Dec 1;40(12):1398–404.
7. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. *Cytokine.* 2013 Feb;61(2):345–8.
8. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. *Rheumatology.* 2010 Sep 1;49(9):1645–53.
9. Ichida H, Kawaguchi Y, Sugiura T, Takagi K, Katsumata Y, Gono T, et al. Clinical manifestations of Adult-onset Still's disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. *Arthritis Care Res.* 2014 Apr;66(4):642–6.
10. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. *Int J Inflamm [Internet].* 2012;2012. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390042/>
11. Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile. *Clin Immunol Orlando Fla.* 2004 Jul;112(1):120–5.
12. Efthimiou P, Moorthy LN, Mavragani CP, Skokos D, Fautrel B. Adult Onset Still's Disease and Autoinflammation. *Int J Inflamm [Internet].* 2012;2012. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437651/>
13. Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review. *Ther Clin Risk Manag.* 2018 Jan;Volume 14:167–71.
14. de Boysson H, Février J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. *Clin Rheumatol.* 2013 Jan;32(1):141–7.

15. Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab Improved both Clinical and Laboratory Manifestations Except for Interleukin-18 in a Case of Multiple Drug-Resistant Adult-Onset Still's Disease. *Intern Med.* 2011;50(16):1757–60.
16. Naniwa T, Ito R, Watanabe M, Hayami Y, Maeda S, Sasaki K, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. *Clin Rheumatol.* 2013 Mar;32 Suppl 1:S103–6.
17. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olivé A, et al. Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients: Tocilizumab in AOSD Refractory to Standard Treatment. *Arthritis Rheumatol.* 2014 Jun;66(6):1659–65.
18. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. *J Rheumatol.* 2010 Nov;37(11):2369–76.
19. Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still's disease in clinical practice. *Autoimmun Rev.* 2017 Oct;16(10):1016–23.
20. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-Onset Still Disease. *Medicine (Baltimore)* [Internet]. 2014 Mar 4 [cited 2015 Dec 18];93(2). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616309/>
21. Al-Homood IA. Biologic treatments for adult-onset Still's disease. *Rheumatology.* 2014 Jan 1;53(1):32–8.
22. Giampietro C, Ridene M, Lequerre T, Chalumeau NC, Amoura Z, Sellam J, et al. Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy. *Arthritis Care Res.* 2013 May 1;65(5):822–6.
23. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease. *Medicine (Baltimore)* [Internet]. 2015 Oct 2 [cited 2015 Dec 17];94(39). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616841/>
24. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. *Arthritis Res Ther.* 2011;13(3):R91.
25. Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still's disease. *Scand J Rheumatol.* 2015 Jul 4;44(4):309–14.
26. Lequerré T, Quartier P, Rosellini D, Alaoui F, Bandt MD, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. *Ann Rheum Dis.* 2008 Mar 1;67(3):302–8.
27. Kim H-A, Sung J-M, Suh C-H. Therapeutic responses and prognosis in adult-onset Still's disease. *Rheumatol Int.* 2012 May;32(5):1291–8.
28. Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. *Clin Rheumatol.* 2006 Sep;25(5):639–44.
29. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. *Arthritis Rheum.* 2010 Aug;62(8):2530–5.

30. Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. *Ann Rheum Dis.* 2005 Feb;64(2):262–6.
31. Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: a meta-analysis. *Mod Rheumatol.* 2017 Dec 18;1–25.
32. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. *Ann Rheum Dis.* 2006 Aug 1;65(8):1117–8.
33. Ostrowski RA, Tehrani R, Kadannoff R. Refractory Adult-Onset Still Disease Successfully Treated With Abatacept: *J Clin Rheumatol.* 2011 Sep;17(6):315–7.
34. Belfeki N, Smiti Khanfir M, Said F, Hamzaoui A, Ben Salem T, Ben Ghorbel I, et al. Successful treatment of refractory adult onset Still's disease with rituximab. *Reumatismo.* 2016 Dec 16;68(3):159.
35. Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still's disease. *Clin Exp Rheumatol.* 2010 Apr;28(2):265–7.
36. Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. *Clin Exp Rheumatol.* 2013 Aug;31(4):657–8.
37. Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. *Clin Exp Rheumatol.* 2009 Oct;27(5):888–9.
38. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. *Ann Rheum Dis.* 2018 Feb 22;annrheumdis – 2017–212608.
39. Chen D-Y, Chen Y-M, Lan J-L, Lin C-C, Chen H-H, Hsieh C-W. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. *Rheumatol Oxf Engl.* 2010 Dec;49(12):2305–12.
40. Choi J-H, Suh C-H, Lee Y-M, Suh Y-J, Lee S-K, Kim S-S, et al. Serum cytokine profiles in patients with adult onset Still's disease. *J Rheumatol.* 2003 Nov;30(11):2422–7.
41. Mimura T, Kondo Y, Ohta A, Iwamoto M, Ota A, Okamoto N, et al. Evidence-based clinical practice guideline for adult Still's disease. *Mod Rheumatol.* 2018 Apr 13;1–53.
42. Guilpain P, Le Quellec A, Maria ATJ. Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine? *Ann Rheum Dis.* 2018 Jun 2;annrheumdis – 2018–213106.

# Tables

## Table 1

**Table 1.** Characteristics of the patients included in the study

n/N* (%)	Systemic form 11 (40.7)	Chronic articular form 16 (59.3)	Total 27
<b>Demographic and clinical</b>			
Sex : female	8 (73)	10 (63)	18 (67)
Age at first symptoms	33 (IQR 23-48)	29 (IQR 21-58.5)	30 (IQR 21-48)
Duration of disease (years)	5 (IQR 2-7)	6.5 (IQR 5-9)	6 (IQR 4-9)
Ever smoked	4 (36)	2/9 (22)	6/20 (30)
Still's disease-related rash	10 (91)	12 (75)	22 (81)
Evanescence erythema	4 (36)	8 (50)	12 (44)
Maculopapular rash	7 (64)	7 (44)	14 (52)
Urticaria rash	3 (27)	2 (13)	5 (18.5)
Arthralgia	10 (91)	16 (100)	26 (96)
Arthritis	3 (27)	11 (69)	14 (52)
Hands affected (arthralgia or arthritis)	9 (82)	14 (88)	23 (85)
EMS	7/8 (88)	13/14 (93)	20/22 (90)
Myalgia	9 (82)	8 (50)	17 (63)
Fever>38°C	11 (100)	16 (100)	27 (100)
Fever>39°C for longer than 7 days	4 (36)	4/15 (27)	8/26 (31)
Intermittent fever	9 (82)	10/15 (67)	19/26 (73)
Vesperal fever	8 (73)	9/15 (60)	17/23 (74)
Deterioration of the general state or weight loss>4kg	8 (73)	10/15 (67)	18/25 (72)
Lymphadenopathy	8 (73)	6/15 (40)	14/26 (54)
Pharyngitis	8 (73)	10/15 (67)	18/26 (69)
Angina	4 (36)	1/15 (7)	5/26 (19)
Visceral involvement	2 (18)	0 (0)	2 (8)
Pleuritis	1 (9)	1 (0)	1 (4)
Pericarditis	1 (9)	2 (0)	1 (4)
Pulmonary hypertension	1 (9)	3 (0)	1 (4)
<b>Biological</b>			
Neutrophilia>8000/mm3	11 (100)	14/15 (93)	25/26 (96)
Eosinophilia>500/mm3	1/10 (10)	0 (0)	1/25 (4)
Anemia<12 g/dl	6/10 (60)	9 (56)	15/26 (58)
Thrombocytosis>400 000/mm3	3/10 (30)	10 (63)	13/26 (50)
Increased C-reactive protein (CRP) levels	11 (100)	16 (100)	27 (100)
Maximum CRP at diagnosis	200 (IQR 160-300)	200 (IQR 67.5-254.5)	200 (IQR 104.5-267.5)
Low albumin	9/10 (90)	9/14 (64)	18/24 (75)
Increased AST or ALT	8 (73)	5/15 (33)	13/26 (50)
Increased ferritin	10 (91)	9/15 (60)	19/26 (73)
Ferritin 1000-5000	4 (36)	6/15 (40)	10/26 (38.5)
Ferritin 5000-10000	2 (18)	1/15 (7)	3/26 (11.5)
Ferritin>10 000	4 (36)	2/15 (13)	6/26 (23)
Glycosylated ferritin<20%	8 (73)	10 (63)	18 (66.7)
Glycosylated ferritin 20-40%	2 (18)	6 (38)	8 (29.6)
Glycosylated ferritin>40%	1 (9)	0 (0)	1 (3.7)
ANA-positivity	2 (18)	3 (19)	5 (18.5)
anti-DNA positivity	0 (0)	1 (6)	1 (3.7)
RF positivity	0 (0)	3 (19)	3 (11)
β2GP1 positivity	1/5 (20)	0 (0)	1/5 (20)
Lupus anticoagulant positivity	1/5 (20)	0 (0)	1/5 (20)
Disseminated intravascular coagulation	0 (0)	0 (0)	0 (0)
rHLH**	3 (27)	0 (0)	3 (11)
Increased triglycerids	5/7 (71)	1/10 (10)	6/17 (35)
Hemophagocytosis	3 (27)	0/5 (0)	3/8 (37.5)

\*N is indicated when data was not available for all 27 patients

\*\* reactive haemophagocytic lymphohistiocytosis

## Table 2

**Table 2.** Delay in corticosteroids withdrawal and detailed responses to anakinra and tocilizumab among the patients included in the study

Phenotype	Corticosteroids			Anakinra-treated patients				Tocilizumab-treated patients			
	Stopped	Delay between diagnosis and steroid withdrawal (months)	bDMARD (months)	Delay between diagnosis and initiation of first anakinra (months)	Anakinra responders	Managed to stop anakinra	Line of treatment	Delay between diagnosis and initiation of tocilizumab (months)	Tocilizumab responders	Managed to stop tocilizumab	Line of treatment
STILL 1	Chronic articular	Yes	12	39	-	-	-	39	Yes	No	Third
STILL 2	Systemic	No	-	0	0	Yes	*	9	No	-	Fourth
STILL 3	Systemic	No	-	1	1	Yes	No	-	-	-	-
STILL 4	Chronic articular	Yes	60	38	-	-	-	38	Yes	No	Second
STILL 5	Chronic articular	Yes	17	7	-	-	-	7	Yes	No	Second
STILL 6	Chronic articular	Yes	71	69	-	-	-	69	Yes	Yes	Third
STILL 7	Systemic	Yes	12	2	2	Yes	No	20	Yes	Yes	Third
STILL 8	Systemic	Yes	20	12	-	-	-	12	Yes	No	Third
STILL 9	Chronic articular	No	-	21	-	-	-	21	Yes	No	Third
STILL 10	Chronic articular	No	-	4	4	No	-	Third and fifth	17	No	Fourth
STILL 11	Systemic	Yes	12	0	0	Yes	Yes	First and third	-	-	-
STILL 12	Chronic articular	No	-	**	-	-	-	**	Yes	No	Third
STILL 13	Chronic articular	Yes	45	24	24	No	-	Third	36	Yes	Fourth
STILL 14	Chronic articular	Yes	18	4	-	-	-	4	Yes	Yes	Second
STILL 15	Chronic articular	Yes	8	1	-	-	-	1	Yes	Yes	Second
STILL 16	Chronic articular	No	-	14	14	Yes	No	Fourth	-	-	-
STILL 17	Chronic articular	Yes	29	17	-	-	-	17	Yes	Yes	Fourth
STILL 18	Systemic	No	-	6	6	Yes	No	Third	-	-	-
STILL 19	Chronic articular	Yes	15	0	-	-	-	0	Yes	No	First
STILL 20	Systemic	No	-	0	0	Yes	Yes	First	-	-	-
STILL 21	Chronic articular	No	-	252	-	-	-	252	Yes	No	Second
STILL 22	Systemic	No	-	0	0	Yes	No	Fist	-	-	-
STILL 23	Systemic	No	-	8	8	Yes	No	Second	0	No	First
STILL 24	Chronic articular	No	-	1	1	Yes	No	Second	-	-	-
STILL 25	Chronic articular	No	-	24	24	Yes	No	Third	-	-	-
STILL 26	Systemic	Yes	6	14	14	Yes	No	Third	-	-	-
STILL 27	Systemic	Yes	53	2	2	Yes	No	Second	-	-	-

\*First, third, fifth and seventh

\*\*Unknown

## Table 3

**Table 3.** Univariate analysis of predictive factors for a good therapeutic response to anakinra or tocilizumab (n=25)

	Anakinra responders (n=12)	Tocilizumab responders (n=13)	p value
<b>Clinical variables</b>			
Sex, F	8	10	0.673
Age at first symptoms	42.5 (IQR 22.5-54)	25 (IQR 21-36)	0.276
Ever smoked	4	2	1.000
Never smoked	4	5	0.170
Still's disease-related rash			
Evanescence erythema	6	6	1.000
Maculopapular rash	6	7	1.000
Urticaria	4	1	0.160
Arthralgia	11	13	0.480
Arthritis	3	10	0.017
Absence of arthritis	9	3	0.017
Hands affected (arthralgia or arthritis)	10	11	1.000
Early morning stiffness	8	11	1.000
Myalgia	9	7	0.411
Fever>39°C for longer than 7 days	5	3	0.667
Intermitent fever	9	9	1.000
Vesperal fever	7	8	0.635
Deterioration of the general state and/or weight loss>4 kg	7	9	0.371
Adenopathy	6	6	1.000
Pharyngitis	9	8	1.000
Angina	4	1	0.317
<b>Phenotypic variables</b>			
Systemic form	9	1	0.0009
Chronic articular form	3	12	0.0009
<b>Biological variables</b>			
Anemia<12g/dl	6	8	1.000
Thrombocytosis>400 000/mm <sup>3</sup>	3	8	0.123
Thrombopénia<150 000/mm <sup>3</sup>	1	0	0.458
Low albumin	8	8	0.646
Ferritin			
5000-10 000 (µg/L)	1	2	1.000
>10 000	3	2	0.645
Glycosylated ferritin<20%	6	10	0.226
ANA positivity	1	4	0.593
Hemophagocytosis	3	0	1.000

## Table 4

**Table 4.** Likelihood of corticosteroid withdrawal stratified by biotherapy

Anakinra responders	Corticosteroids stopped			p value
	No	Yes	Total	
No	1	1	2	
Yes	9	4	13	
<i>Total</i>	10	5	15	
				1.000
Tocilizumab responders	Corticosteroids stopped			p value
	No	Yes	Total	
No	3	0	3	
Yes	3	11	14	
<i>Total</i>	6	11	17	
				0.029

# Serment d'Hippocrate



Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.

Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.

Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité.

J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences.

Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences.

Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés.

Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.

Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.

Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré et méprisé si j'y manque.

”

**Prénom: François**  
**Nom: Vercruyse**  
**Spécialité : Rhumatologie**  
**U.F.R. des Sciences Médicales, Université de Bordeaux**

---

## **La stratégie de traitement par biothérapie de la maladie de Still de l'adulte dépend de la dichotomie phénotypique**

**Introduction:** Le phénotype de la maladie de Still de l'adulte (MSA) peut être dichotomisé en une forme systémique et une forme articulaire chronique. A l'ère où les biothérapies et notamment le blocage des interleukines (IL)-1 et 6 jouent un rôle prépondérant dans son traitement, leurs place dans la stratégie thérapeutique reste à préciser. Cette étude avait pour objectif d'identifier des facteurs prédictifs cliniques ou biologiques de réponse préférentielle à l'anakinra ou au tocilizumab, et d'identifier si le choix de biothérapie et son délai d'initiation influençaient les chances de sevrage cortisonique.

**Méthodes:** Une étude exploratoire multicentrique rétrospective a inclus tous les patients atteints de MSA et ayant reçu une biothérapie dans trois hôpitaux régionaux jusqu'à 2018. Leur caractéristiques cliniques et biologiques au diagnostic et les données relatives aux traitements ont été recueillies. Une analyse univariée a été effectuée en utilisant le test statistique non-paramétrique de Mann-Whitney pour les variables quantitatives et le test exact de Fisher pour les variables qualitatives.

**Résultats:** Vingt-sept patients ont été inclus. Tous les patients sauf un ont atteint la rémission soit sous anakinra soit sous tocilizumab. La réponse au traitement dépendait du phénotype clinique : la présence d'arthrite et un phénotype articulaire chronique étaient associés à une réponse thérapeutique préférentielle pour le tocilizumab ( $p=0.017$  et  $p=0.0009$  respectivement), alors qu'une forme systémique et l'absence d'arthrite étaient associées à une réponse thérapeutique préférentielle à l'anakinra ( $p=0.017$  et  $p=0.0009$  respectivement). Le tocilizumab était associé à de meilleures chances de sevrage cortisonique ( $p=0.029$ ) quel que soit son délai d'initiation ou sa place en terme de ligne thérapeutique.

**Conclusion:** Cette étude souligne l'importance de la dichotomisation phénotypique de la MSA et ses implications thérapeutiques. Ces résultats devraient nous permettre de mieux catégoriser les patients atteints de MSA et nous aider à codifier leur traitement.

**Mots-clés:** *Maladie de Still de l'Adulte, Traitements Biologiques, Corticoïdes, Maladies auto-inflammatoires*

---

## **Adult-Onset Still's Disease Biological Treatment Strategy Depends on the Phenotypic Dichotomy**

**Objectives:** Adult-onset Still's disease (AOSD) phenotype can be dichotomized in systemic or chronic articular forms. As biologicals and particularly interleukin (IL)-1 and IL-6 blockers play a more and more prominent role in the treatment, their place requires clarification. This study aimed to identify factors predictive of treatment response to anakinra or tocilizumab, and investigate whether the choice of biotherapy and delays in the initiation of biotherapy influenced the likelihood of steroid discontinuation.

**Methods:** A multicenter exploratory retrospective study included all patients diagnosed with AOSD and receiving biological treatments in three regional hospitals until 2018. Clinical and biological characteristics at diagnosis and treatment related data were collected. The non-parametric Mann-Whitney test was used to perform univariate analysis for quantitative variables, and Fisher's exact test was used for qualitative variables.

**Results:** Twenty-seven patients were included. All but one patient achieved remission with either anakinra or tocilizumab. Treatment responses depended on disease phenotype: the presence of arthritis and a chronic articular phenotype were associated with a preferential response to tocilizumab with  $p=0.0009$  and  $p=0.017$  respectively, whereas the systemic form and the absence of arthritis were associated with a preferential response to anakinra with  $p=0.0009$  and  $p=0.017$  respectively. Tocilizumab increased the likelihood of corticosteroid withdrawal ( $p=0.029$ ) regardless of delays in initiation or when it was initiated relative to other treatment in the overall therapeutic strategy.

**Conclusion:** This study highlights the therapeutic implications of the phenotypic dichotomy of AOSD and should help us better codify AOSD treatment.

**Keywords:** *Adult-Onset Still's disease, Biologicals, Corticosteroids, Miscellaneous Rheumatic and Inflammatory Diseases*